Lennox–Gastaut syndrome

Sixth Annual Lennox-Gastaut Syndrome (LGS) Walk Scheduled for June 5 is Raising Critical Funds for Research

Monday, May 31, 2021 - 11:00am

The 6th Annual LGS Foundation Walk 'n' Wheel is hosted by the LGS Foundation and will celebrate the ability of those with LGS, who suffer many challenges due to frequent, uncontrolled seizures, to walk, ride, and wheel in their wheelchairs all to raise funds for research into disease-modifying therapies and cures for LGS.

Key Points: 
  • The 6th Annual LGS Foundation Walk 'n' Wheel is hosted by the LGS Foundation and will celebrate the ability of those with LGS, who suffer many challenges due to frequent, uncontrolled seizures, to walk, ride, and wheel in their wheelchairs all to raise funds for research into disease-modifying therapies and cures for LGS.
  • LGS is a rare, severe, life-threatening, epilepsy that leads to frequent seizures, significant brain damage, and a lifelong dependence on others for their care.
  • All funds we raise from the Walk 'n' Wheel will go to support research."
  • The LGS Foundation is the only global organization dedicated to improving the lives of the many families impacted by LGS by raising awareness of LGS, supporting and educating families, and funding critical scientific research.

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

Wednesday, May 12, 2021 - 1:00pm

b'NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.\nA live audio webcast of the virtual fireside chat can be accessed through the Events & Presentations section of the Company\xe2\x80\x99s website at investors.ovidrx.com .

Key Points: 
  • b'NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.\nA live audio webcast of the virtual fireside chat can be accessed through the Events & Presentations section of the Company\xe2\x80\x99s website at investors.ovidrx.com .
  • We continue to execute on our strategy to build this pipeline by discovering, in-licensing and collaborating with leading biopharmaceutical companies and academic institutions.
  • Additionally, Ovid maintains a significant financial interest in a program directed to the exploitation of soticlestat, for which Takeda is responsible for the global development and commercialization, if soticlestat is successfully developed and commercialized.
  • Two phase 3 trials for soticlestat in Dravet syndrome and Lennox-Gastaut syndrome are expected to begin in mid-2021.\nFor more information on Ovid, please visit www.ovidrx.com .\n'

Zogenix to Participate in the BofA Securities 2021 Healthcare Conference

Tuesday, May 11, 2021 - 9:01pm

b'Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • b'Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The company\xe2\x80\x99s first rare disease therapy, FINTEPLA\xc2\xae (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
  • The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
  • Zogenix plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.\n'

Zogenix to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 6

Thursday, April 22, 2021 - 1:00pm

b'Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • b'Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The company\xe2\x80\x99s first rare disease therapy, FINTEPLA\xc2\xae (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
  • The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
  • Zogenix plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.\n'

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex

Tuesday, April 20, 2021 - 11:30am

\xe2\x80\x9cWe now look forward to working with each European member state to make EPIDYOLEX\xc2\xae available to appropriate patients across Europe, as quickly as possible.\xe2\x80\x9d\nDr.

Key Points: 
  • \xe2\x80\x9cWe now look forward to working with each European member state to make EPIDYOLEX\xc2\xae available to appropriate patients across Europe, as quickly as possible.\xe2\x80\x9d\nDr.
  • Volker Knappertz, GW\xe2\x80\x99s Chief Medical Officer, said, \xe2\x80\x9cWe are excited by the news of this approval by the European Commission and the benefits EPIDYOLEX could bring to the community.
  • In the U.S., EPIDIOLEX\xc2\xae is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome or Tuberous Sclerosis Complex (TSC) in patients one year of age and older.
  • It is associated with an increased risk of autism and intellectual disability.1 The severity of the condition can vary widely.

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex

Tuesday, April 20, 2021 - 11:30am

\xe2\x80\x9cWe now look forward to working with each European member state to make EPIDYOLEX\xc2\xae available to appropriate patients across Europe, as quickly as possible.\xe2\x80\x9d\nDr.

Key Points: 
  • \xe2\x80\x9cWe now look forward to working with each European member state to make EPIDYOLEX\xc2\xae available to appropriate patients across Europe, as quickly as possible.\xe2\x80\x9d\nDr.
  • Volker Knappertz, GW\xe2\x80\x99s Chief Medical Officer, said, \xe2\x80\x9cWe are excited by the news of this approval by the European Commission and the benefits EPIDYOLEX could bring to the community.
  • In the U.S., EPIDIOLEX\xc2\xae is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome or Tuberous Sclerosis Complex (TSC) in patients one year of age and older.
  • It is associated with an increased risk of autism and intellectual disability.1 The severity of the condition can vary widely.

Zogenix to Participate in the 20th Annual Needham Virtual Healthcare Conference

Thursday, April 8, 2021 - 1:00pm

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
  • The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency.
  • Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

AHN Hospitals First in Western Pennsylvania to use Advanced Seizure Monitoring Technology for Optimized Care of Critically Ill Patients

Friday, April 2, 2021 - 12:00pm

Patients who are critically ill or injured can experience non-convulsive seizures, as the body's central nervous system reacts to trauma or a serious disease process at work.

Key Points: 
  • Patients who are critically ill or injured can experience non-convulsive seizures, as the body's central nervous system reacts to trauma or a serious disease process at work.
  • Since the patient shows no outward signs of seizure activity, physicians must rely on electroencephalography or EEG monitoring, which is not always readily available, to detect it.
  • About the Allegheny Health Network:
    Allegheny Health Network (AHN.org), a Highmark Health company, is an integrated healthcare delivery system serving the greater Western Pennsylvania region.
  • Ceribell is focused on making EEG widely available, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures.

Fintepla (ZX008): Sold Under the Brand Name Fintepla - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Wednesday, March 10, 2021 - 2:29pm

The "Fintepla (ZX008) - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fintepla (ZX008) - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • "Fintepla (ZX008)- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Lennox Gastaut Syndrome in 7 Major Markets.
  • Fintepla (ZX008) is the oral medication low-dose solution of fenfluramine hydrochloride used in the treatments to reduce the frequency of seizures.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Perampanel: Approved by FDA for the Treatment of Partial-Onset Seizures (POS) - Global Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

Tuesday, March 9, 2021 - 3:17pm

The "Perampanel - Emerging Insights and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Perampanel - Emerging Insights and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • "Perampanel - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Lennox Gastaut Syndrome in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Perampanel has been approved by FDA for the treatment of "partial-onset seizures (POS) with or without secondary generalized seizures" in patients as young as 4 years.